For the quarter ending 2025-09-30, RGPX had -$160,771 decrease in cash & cash equivalents over the period.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -814,012 | -663,584 |
| Depreciation and amortization | 1,157 | 1,259 |
| Foreign currency adjustment | -539 | -6,092 |
| Stock-based compensation | 177,867 | 257,133 |
| Amortization of rou assets, net of liabilities | -3,348 | -13,348 |
| Prepaid expenses | -16,520 | -19,900 |
| Accounts payable | 47,481 | -26,405 |
| Accrued compensation | -54,593 | 20,250 |
| Other accrued liabilities | 142,074 | -39,440 |
| Net cash used in operating activities | -519,355 | -477,943 |
| Capitalized software development | 38,472 | - |
| Purchase of furniture and computer equipment | 446 | 0 |
| Net cash used in investing activities | -38,918 | 0 |
| Repayment of notes payable to related parties | 87,498 | 17,652 |
| Related party advances, net | - | 0 |
| Proceeds from sale of common stock and warrants | 485,000 | 15,000 |
| Proceeds from notes payable to related parties | - | 0 |
| Net cash provided by financing activities | 397,502 | -2,652 |
| Increase (decrease) in cash and equivalents | -160,771 | -480,595 |
| Cash and cash equivalents at beginning of period | 653,025 | - |
| Cash and cash equivalents at end of period | 11,659 | - |
REGENEREX PHARMA, INC. (RGPX)
REGENEREX PHARMA, INC. (RGPX)